业绩总结 - 2025年第三季度总收入达到2.168亿美元，同比增长113%[10] - 分子分析服务收入增长至2.076亿美元，同比增长121%[10] - 制药研发服务收入增长至92万美元，同比增长18%[10] - 临床收入增长至2.184亿美元，同比增长18%[12] - 临床案例完成量为50,763，同比增长18%[13] - 报告的毛利率为68%，改善约2,432个基点[13] - 实现调整后EBITDA为5,120万美元，GAAP净收入为2,430万美元[13] - 自由现金流为5,530万美元[13] 用户数据 - 数据集超过959,000个基因组分析，包含660,000个匹配的分子数据和临床结果[13] - 2025年第三季度临床平均售价（ASP）提升至4,089美元，同比增长87%[13] - 2025年第三季度血液治疗选择的平均销售价格（ASP）为3,034美元，同比增长78.8%[47] - 2025年第三季度组织治疗选择的平均销售价格（ASP）为4,273美元，同比增长90.7%[47] 未来展望 - 更新后的2025年财务指导显示，总收入预期为720至730百万美元，同比增长75%至77%[50] 成本与费用 - 2025年第三季度组织销售和市场费用为41.3百万美元，较2024年第三季度的36.8百万美元增加了4.5百万美元[43] - 2025年第三季度研发费用为21.6百万美元，较2024年第三季度的27.6百万美元减少了6.0百万美元[43] 现金流与资产 - 2025年第三季度现金及投资总额为759.3百万美元，较2024年12月31日的70.2百万美元增加了689.1百万美元[43] - 2025年第三季度调整后EBITDA为51.2百万美元，较2024年第三季度的-45.6百万美元改善了96.8百万美元[43] - 2025年第三季度净利润为24.3百万美元，较2024年第三季度的-67.7百万美元改善了92.1百万美元[43] - 2025年第三季度自由现金流为55.3百万美元，较2024年第三季度的-71.3百万美元改善了126.6百万美元[43]

Q3 2025 Business & Financial Highlights November 5, 2025 2 IonQ Q3 2025 Update Copyright © 2025 IonQ, Inc. All Rights Reserved. Unprecedented Momentum and Scale The Quantum Leader in Every Metric That Matters Oak Ridge National Laboratory Copyright © 2025 IonQ, Inc. All Rights Reserved. Important Information Forward-Looking Statements and Other Information This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, including ...

2 INVESTOR PRESENTATION NOVEMBER 2025 DISCLOSURES FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product and ...

Q2 FY26 Earnings Presentation Nov 5, 2025 Cautionary Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, regarding LiveRamp's (the "Company") future business prospects. These statements involve risks and uncertainties that could cause the Company's actual results to differ materially, including, but not limited to competit ...

November 5, 2025 EPIDIOLEX ® patient diagnosed with Dravet syndrome November 5, 2025 Markella Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the Company's 2025 financial guidance and the Company's expectations related thereto, including with respect t ...

On Target to Outsmart Cancer November 2025 © 2025 Revolution Medicines, Inc. 2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to manage existing collaborations and estab ...

Revolutionizing Medicines and Materials Discovery These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond our control, including the demand for our so ...

业绩总结 - 2025年第三季度总收入为8.1亿美元，同比增长21%[16] - 2025年第三季度订阅收入为7.92亿美元，同比增长21%[16] - 2025年第三季度毛利润为6.89亿美元，毛利率为85%[16] - 2025年第三季度运营利润为1.61亿美元，运营利润率为20%[16] - 2025年第四季度指导总收入预计在8.28亿至8.30亿美元之间，同比增长18%[18] - 2025年全年总收入指导预计在31.13亿至31.15亿美元之间，同比增长19%[21] - 2025年第三季度自由现金流为1.47亿美元，同比增长14%[16] - 从2019年第一季度到2025年第三季度，收入年复合增长率为29%[25] - 从2019年第一季度到2025年第三季度，客户数量年复合增长率为26%[28] 未来展望 - 2025年运营利润率指导为18%[21] - 2025年12月31日的非GAAP运营收入预期范围为183,000千美元至184,000千美元[47] - 2025年12月31日的非GAAP净收入预期范围为511,000千美元至512,000千美元[47] - 2025年12月31日的GAAP净收入预期范围为33,673千美元至34,923千美元[47] - 2025年12月31日的GAAP运营收入预期范围为39,114千美元至40,114千美元[47] 负面信息 - 2023年12月31日的GAAP运营亏损为(10,849)千美元，亏损率为-1.5%[45] - 2023年6月30日的GAAP运营亏损为(116,169)千美元，亏损率为-22.0%[45] 其他信息 - 2023年12月31日的非GAAP运营收入为133,072千美元，占收入的18.9%[45] - 2023年6月30日的非GAAP运营收入为76,565千美元，占收入的14.5%[45] - 2025年6月30日的自由现金流预期为530,779千美元[46]

3Q 2025 FINANCIAL RESULTS NOVEMBER 5, 2025 FORWARD-LOOKING STATEMENTS This presentation and the related earnings press release contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words such as "anticipate," "believe," "consider," "contempl ...

November 2025 Investor Presentation 2 About non-GAAP financial measures This presentation includes certain non-GAAP financial measures including Adjusted EBITDA, Adjusted EBITDA margin, non-GAAP net income (loss), non-GAAP net income (loss) margin, non-GAAP gross profit, Non-GAAP gross profit margin, certain non-GAAP expenses (including non-GAAP cost of revenue, non-GAAP sales and marketing, non-GAAP technology and development, and non-GAAP general and administrative), free cash flow and free cash flow marg ...